TY - JOUR
T1 - Malignancy Risk and Recurrence with Psoriasis and its Treatments
T2 - A Concise Update
AU - Geller, Shamir
AU - Xu, Haoming
AU - Lebwohl, Mark
AU - Nardone, Beatrice
AU - Lacouture, Mario E.
AU - Kheterpal, Meenal
N1 - Funding Information:
Funding This research was funded in part through the National Institutes of Health/National Cancer Institute (NIH/NCI) Cancer Center Support Grant P30 CA008748.
Funding Information:
This research was funded in part through the National Institutes of Health/National Cancer Institute (NIH/NCI) Cancer Center Support Grant P30 CA008748. Dr. Lebwohl is an employee of the Icahn School of Medicine at Mount Sinai, which receives research funds from Abbvie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, Kadmon, Medimmune/AstraZeneca, Novartis, and Pfizer. Dr. Lacouture has consulting agreements with Quintiles, Boehringer Ingelheim, AstraZeneca Pharmaceuticals, Legacy Healthcare, Foamix, Adgero Biopharmaceuticals, Janssen R&D, Novartis and Novocure, and receives research grants from Berg and Bristol-Myers Squibb. Dr. Geller, Mr Xu, Dr. Nardone and Dr. Kheterpal have no conflicts of interest to declare.
Funding Information:
Conflict of interest Dr. Lebwohl is an employee of the Icahn School of Medicine at Mount Sinai, which receives research funds from Abbvie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, Kadmon, Medimmune/AstraZeneca, Novartis, and Pfizer. Dr. Lacouture has consulting agreements with Quintiles, Boehringer Ingelheim, AstraZeneca Pharmaceuticals, Legacy Healthcare, Foa-mix, Adgero Biopharmaceuticals, Janssen R&D, Novartis and Novocure, and receives research grants from Berg and Bristol-Myers Squibb. Dr. Geller, Mr Xu, Dr. Nardone and Dr. Kheterpal have no conflicts of interest to declare.
Publisher Copyright:
© 2017, Springer International Publishing AG, part of Springer Nature.
PY - 2018/6/1
Y1 - 2018/6/1
N2 - Psoriasis is a common inflammatory cutaneous disease that affects approximately 120 million people worldwide. Systemic treatments have significantly improved disease burden, but concerns persist regarding their association with increased risk of malignancy. Patients with psoriasis have a slightly elevated baseline risk of lymphoproliferative diseases. Studies on methotrexate and cyclosporine, as well as older biological agents such as tumor necrosis factor inhibitors, have found no increased risk of non-cutaneous solid tumors; however, positive associations between cutaneous squamous cell carcinomas and certain therapies have been found. There is conflicting evidence regarding the risk of lymphoma and melanoma. Further studies are needed to determine the long-term safety of newer psoriasis treatments (interleukin [IL]-12/23, IL-17, Janus kinase 1/3, and phosphodiesterase-4 inhibitors), specifically their safety in patients with a history of cancer. This review summarizes the most recent studies on malignancy risk from psoriasis, and its treatments in patients and cancer survivors, with the highest available level of evidence.
AB - Psoriasis is a common inflammatory cutaneous disease that affects approximately 120 million people worldwide. Systemic treatments have significantly improved disease burden, but concerns persist regarding their association with increased risk of malignancy. Patients with psoriasis have a slightly elevated baseline risk of lymphoproliferative diseases. Studies on methotrexate and cyclosporine, as well as older biological agents such as tumor necrosis factor inhibitors, have found no increased risk of non-cutaneous solid tumors; however, positive associations between cutaneous squamous cell carcinomas and certain therapies have been found. There is conflicting evidence regarding the risk of lymphoma and melanoma. Further studies are needed to determine the long-term safety of newer psoriasis treatments (interleukin [IL]-12/23, IL-17, Janus kinase 1/3, and phosphodiesterase-4 inhibitors), specifically their safety in patients with a history of cancer. This review summarizes the most recent studies on malignancy risk from psoriasis, and its treatments in patients and cancer survivors, with the highest available level of evidence.
UR - http://www.scopus.com/inward/record.url?scp=85046126894&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046126894&partnerID=8YFLogxK
U2 - 10.1007/s40257-017-0337-2
DO - 10.1007/s40257-017-0337-2
M3 - Review article
C2 - 29260411
AN - SCOPUS:85046126894
VL - 19
SP - 363
EP - 375
JO - American Journal of Clinical Dermatology
JF - American Journal of Clinical Dermatology
SN - 1175-0561
IS - 3
ER -
